Rock Springs Capital Management LP Grows Stock Position in Pharvaris (NASDAQ:PHVS)

Rock Springs Capital Management LP boosted its position in Pharvaris (NASDAQ:PHVS - Free Report) by 2.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 775,131 shares of the company's stock after acquiring an additional 18,200 shares during the quarter. Rock Springs Capital Management LP owned 1.48% of Pharvaris worth $14,859,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Legal & General Group Plc raised its holdings in shares of Pharvaris by 11.2% in the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after purchasing an additional 994 shares in the last quarter. FMR LLC raised its stake in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after buying an additional 189,714 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock worth $735,000 after buying an additional 1,356 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after acquiring an additional 2,847 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Pharvaris in the 4th quarter valued at about $111,000.

Pharvaris Stock Up 6.4 %

PHVS traded up $1.01 on Friday, reaching $16.84. The company had a trading volume of 559,870 shares, compared to its average volume of 70,785. Pharvaris has a 1 year low of $11.51 and a 1 year high of $25.50. The stock has a market capitalization of $880.56 million, a PE ratio of -6.01 and a beta of -2.84. The stock has a 50-day moving average price of $14.94 and a 200-day moving average price of $18.10.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.06. As a group, analysts expect that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities boosted their target price on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Friday, January 31st.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.